Recurrent Optic Neuritis (rON) is characterised by Anti-MOG Antibodies: A follow-up study (P5.274)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To investigate patients with recurrent optic neuritis (rON) for anti-MOG antibodies. Background: Autoantibodies to myelin oligodendrocyte glycoprotein (MOG) have been identified in some patients with inflammatory demyelinating diseases including pediatric multiple sclerosis (MS), acute disseminated encephalomyelitis (ADEM) and AQP4-seronegative NMO spectrum disorders (NMOSD). rON refers to a clinically distinct subset of patients, thought to fall within the rubric of NMODS. These patients characteristically exhibit several steroid-sensitive episodes of optic neuritis (ON) and do not develop spinal cord symptomatology. Methods: We examined sera from 111 AQP4-negative patients with clinical features of either multiple sclerosis or NMOSD using a cell-based assay, which detects structural and extracellular anti-MOG epitopes. Screening was performed with human embryonic kidney cells, transiently transfected with MOG C-terminally fused to EGFP. Results: Anti-MOG antibodies were detected in 8 patients with ON; 5 of them were diagnosed as definite rON because they had 蠅3 episodes of ON without any other clinical symptomatology. Brain/orbital MRI or CSF analyses (when available) were normal except for optic nerve enhancement in two of them. Spinal cord MRI depicted a small subclinical chronic lesion in the cervical spine in one of 8 patients who never developed clinical symptoms of myelitis during our follow-up period. All anti-MOG-positive patients were steroid responsive but two of them, required other immunosuppressants, plasmapheresis or IVIG to suppress or prevent relapses. Conclusion: Patients with the clinically distinct entity of rON (AQP4-negative) are characterized by antibodies against MOG. Because anti-MOG antibodies have been also detected in typical NMOSD (either AQP4-negative or AQP4-positive), different MOG epitopes may distinguish rON from NMOSD. Whether in rON patients the anti-MOG antibodies are causally connected to conduction block in the optic nerve or demyelination is unclear. The pathogenicity of these antibodies is currently explored on optic nerve ex vivo preparations in our laboratory.
Disclosure: Dr. Chalmoukou has nothing to disclose. Dr. Stathopoulos has nothing to disclose. Dr. Alexopoulos has nothing to disclose. Dr. Akrivou has nothing to disclose. Dr. Dalakas has received personal compensation for activities with Baxter, Novartis, Grifols, CSL, Octapharma, Dysimmune Diseases Foundation, and Therapath. Dr. Dalakas has received personal compensation in an editorial capacity for Therapeutic Advances i
Wednesday, April 22 2015, 2:00 pm-6:30 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Related Articles
- No related articles found.